Phaseline

Companies › Vironexis Biotherapeutics

Vironexis Biotherapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 2 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
VNX-101
Adeno-associated viral vector encoding CD3/CD19 bi-specific T-cell engager
CD3, CD19Phase 1B-cell Acute Lymphoblastic LeukemiaJun 2027
VNX-202
Adeno-associated viral vector encoding CD3/HER2 bi-specific T-cell engager
CD3, ERBB2Phase 1HER2 Expressing Solid TumorsSep 2033

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06533579VNX-101Phase 1B-cell Acute Lymphoblastic LeukemiaOncologyJun 2027
NCT07192432VNX-202Phase 1HER2 Expressing Solid TumorsOncologySep 2033

Targets

CD3 (2) CD19 (1) ERBB2 (1)

Companies with the same targets

Beijing Biotech Roche Gilead Sciences Bristol-Myers Squibb Chongqing Precision Biotech Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical AstraZeneca Kali Therapeutics Chia Tai Tianqing Pharmaceutical Group Allogene Therapeutics

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.